Cardiovascular system

Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)

Retrieved on: 
Tuesday, June 8, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Cardiovascular system, Circulatory system, Cardiology, Heart diseases, Percutaneous coronary intervention, Coronary occlusion, Coronary artery disease, Angina, Coronary Microvascular Obstruction, Temanogrel, Arena Pharmaceuticals, CORONARY MICROVASCULAR OBSTRUCTION, TEMANOGREL, ARENA PHARMACEUTICALS

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first participant has been randomized in a Phase 2 trial evaluating IV temanogrel, an investigational, peripherally acting, and selective 5-HT2A receptor inverse agonist, for the potential treatment of coronary microvascular obstruction (cMVO) in patients undergoing percutaneous coronary intervention (PCI).

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first participant has been randomized in a Phase 2 trial evaluating IV temanogrel, an investigational, peripherally acting, and selective 5-HT2A receptor inverse agonist, for the potential treatment of coronary microvascular obstruction (cMVO) in patients undergoing percutaneous coronary intervention (PCI).
  • As there are no currently FDA-approved treatment options for patients with cMVO, the clinical advancement of a novel molecule like temanogrel for this patient population is exciting."
  • Coronary microvascular obstruction (cMVO) is a condition characterized by the failure to achieve full myocardial or microcirculatory reperfusion despite resolution of epicardial coronary occlusion and flow by a percutaneous coronary intervention (PCI).
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Global Pulmonary Arterial Hypertension Market and Forecast Analysis Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Health, Cardiology, Hypertension, Anatomy, Chemistry, Cardiovascular system, Pulmonary hypertension, Chronic thromboembolic pulmonary hypertension, Selexipag, Pulmonary artery, PAH, Actelion

The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report estimates that in 2018, there were approximately 218,500 prevalent cases of pulmonary arterial hypertension (PAH) in individuals of all ages worldwide, and forecasts that number to increase to 241,800 prevalent cases by 2027.
  • Additionally, this will markedly expand the prostacyclin class's potential by encouraging first-line uptake alongside Opsumit, which is a market leader.
  • Market leaders Opsumit and Uptravi are being investigated in clinical trials to potentially support label expansions to chronic thromboembolic pulmonary hypertension (CTEPH).

The University of Sydney secured a AU$1.4M grant plus AU$2M from industry and partners with Allelica, Inc. to advance heart disease prevention strategies through Polygenic Risk Score application

Retrieved on: 
Monday, June 7, 2021
Circulatory system, Cardiovascular system, Cardiovascular diseases, Aging-associated diseases, Acute pain, Coronary artery disease, Medical emergencies, Cardiovascular disease, Polygenic score, Myocardial infarction, Preventive healthcare, Carotid artery stenosis

The University of Sydney has chosen to partner with Allelica to advance preventive healthcare strategies for coronary artery disease through the clinical application of polygenic risk score in risk assessment.

Key Points: 
  • The University of Sydney has chosen to partner with Allelica to advance preventive healthcare strategies for coronary artery disease through the clinical application of polygenic risk score in risk assessment.
  • The project is focused on improving heart disease prevention strategies through the application of Allelica's PRS in precision risk assessment.
  • Existing risk assessments for coronary artery disease focus on cholesterol levels and other risk factors such as smoking status, age and blood pressure.
  • Consequently, these patients are not prescribed the prevention strategies necessary to reduce the possibility of a heart attack or stroke.

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions

Retrieved on: 
Thursday, June 3, 2021
Cardiac arrhythmia, Branches of biology, Circulatory system, Cardiovascular system, Fibrillation, Arrhythmia, Atrium, Premature ventricular contraction, Atrial fibrillation, Rhythm interpretation, Premature atrial contraction

Anavexs newest patent is expected to remain in force at least until 2038, not including any patent term extensions.

Key Points: 
  • Anavexs newest patent is expected to remain in force at least until 2038, not including any patent term extensions.
  • The new patent will expand the use of ANAVEX2-73 (blarcamesine) from neurodegenerative and neurodevelopmental disorders to a range of cardiac dysfunctions.
  • It includes cardiac arrhythmia, premature ventricular contraction (PVC), ventricular dysfunction, ventricular arrhythmia, atrial fibrillation, and atrial flutter, among others.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Afimmune Announces Positive Data with Epeleuton from Preclinical Atherosclerosis Studies

Retrieved on: 
Thursday, June 3, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical trials, Medical specialties, Circulatory system, Cardiovascular system, GABAA receptor positive allosteric modulators, Atherosclerosis, Cholesterol, Niacin, Omega-3 fatty acid, High-density lipoprotein, Cardiovascular disease, Epeleuton, the TRIAGE trial, Afimmune, EPELEUTON, THE TRIAGE TRIAL, AFIMMUNE

Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies.

Key Points: 
  • Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies.
  • Any new therapeutic that can decrease or prevent atherosclerosis is expected to have a significant impact on cardiovascular outcomes, including mortality.
  • In addition to these large reductions in atherosclerosis progression, epeleuton statistically significantly decreased triglycerides, cholesterol and inflammatory markers, including serum interleukin-1 beta (IL-1).
  • The strong effects of epeleuton on atherosclerosis, shown for the first time in these preclinical studies, further emphasises the exciting therapeutic potential of this novel omega 3 drug.

COVID-19 Increases Rate of Heart Attacks in People with Genetic High Cholesterol and Heart Disease

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Circulatory system, Cardiovascular system, Lipid metabolism disorders, Cardiology, Lipoproteins, Cardiovascular diseases, Familial hypercholesterolemia, Hypercholesterolemia, Cholesterol, Low-density lipoprotein, Coronary artery disease

PASADENA, Calif., May 27, 2021 /PRNewswire/ --Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation .

Key Points: 
  • PASADENA, Calif., May 27, 2021 /PRNewswire/ --Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation .
  • Published online in the American Journal of Preventive Cardiology, the study also importantly confirms that COVID-19 increases heart attack rates in individuals with established atherosclerotic cardiovascular disease (ASCVD).
  • The researchers found that rates of heart attacks were highest in those with a COVID-19 diagnosis and the presence of diagnosed FH or probable FH with known ASCVD.
  • Familial hypercholesterolemia is a common genetic condition that increases an individual's risk for cardiovascular disease by up to 20-fold due to lifelong elevated low density lipoprotein cholesterol (LDL-C) levels.

Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System

Retrieved on: 
Thursday, May 27, 2021
Catheter ablation, Circulatory system, Cardiac arrhythmia, Clinical medicine, Cardiovascular system, Atrial fibrillation, Arrhythmia, Heart, Ablation, Sensei robotic catheter system, Topera Medical

CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.

Key Points: 
  • CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.
  • In contrast to most contemporary ablation systems, the AcQBlate Force Catheter and System can operate both in a stand-alone manner or in conjunction with compatible 3D mapping systems.
  • The new ablation system is comprised of Acutus AcQBlate Force Catheter and Qubic Force module and seamlessly integrates with the Qubic RF generator and Qiona irrigation pump.
  • Ariyarathna N. et al., Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias: Evolution or History Repeating Itself?

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Angiology, Vascular diseases, Cardiovascular system, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Stroke, Carotid artery, NASDAQ

TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).

Key Points: 
  • TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

Varian Receives FDA "Breakthrough Device Designation" for its Cardiac Radioablation (CRA) System for Treatment of Refractory Ventricular Tachycardia (VT)

Retrieved on: 
Wednesday, May 26, 2021
Cardiac arrhythmia, Circulatory system, Cardiovascular system, Branches of biology, Ventricular tachycardia, Tachycardia, Catheter ablation, Sinus tachycardia, Cardiac electrophysiology

Ventricular tachycardia is a fast, abnormal heart rate and may lead to sudden cardiac arrest if not treated successfully.

Key Points: 
  • Ventricular tachycardia is a fast, abnormal heart rate and may lead to sudden cardiac arrest if not treated successfully.
  • "As a heart rhythm specialist who routinely treats individuals with VT, I am thrilled to see the FDA recognize Varian's cardiac radioablation system as a breakthrough technology.
  • "Early positive clinical results suggest that non-invasive cardiac radioablation could offer new hope for patients with refractory VT," said Kolleen Kennedy, President, Proton Solutions and Growth Office, Varian.
  • Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial.

Hello Heart Completes $45M Investment to Fuel Growth and Expand Digital Heart Health

Retrieved on: 
Wednesday, May 26, 2021
Technology, Medical devices, General Health, Professional services, Science, Fitness & Nutrition, Medical Supplies, Cardiology, Biotechnology, Health, Other Science, Software, Mobile, Wireless, Data management, Finance, Venture capital, Consumer electronics, Anatomy, Cardiovascular diseases, Circulatory system, Behavior modification, Digital therapeutics, Cardiovascular system, Blood pressure, Aging-associated diseases, Cardiovascular disease, Heart, Hypertension, Hello Heart, IVP, HELLO HEART, IVP

Hello Heart , the best-in-class heart health digital therapeutics solution, has completed a $45 million Series C led by IVP.

Key Points: 
  • Hello Heart , the best-in-class heart health digital therapeutics solution, has completed a $45 million Series C led by IVP.
  • Hello Hearts mission is to empower people to manage and improve their heart health using digital technology.
  • Hello Heart is the only digital therapeutic hypertension solution with a peer-reviewed clinical study on blood pressure outcomes.
  • Hello Heart has an opportunity to become the digital therapeutics leader for all cardiovascular diseases and were excited to partner with them on their growth phase.